Screener
Cytek Biosciences, Inc. CTKB Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Cytek Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Cytek Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-032293
| (In thousands) | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Legal settlement liabilities | (389) | (365) |
| Operating lease liabilities | (159) | (1,035) |
| Deferred revenue | 1,175 | 1,343 |
| Net cash (used in) operating activities | (2,736) | (125) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (95,598) | (60,161) |
| Proceeds from maturities of marketable securities | 70,714 | 70,431 |
| Proceeds from sale of property and equipment | 6 | 33 |
Item 1. Consolidated Financial Statements (Unaudited)
FAQ
- What is Cytek Biosciences, Inc.'s operating cash flow?
- Cytek Biosciences, Inc. (CTKB) reported operating cash flow of -$2.74M in Q1 2026.
- How has Cytek Biosciences, Inc.'s operating cash flow changed year-over-year?
- Cytek Biosciences, Inc.'s operating cash flow decreased by 2088.8% year-over-year, from -$125K to -$2.74M.
- What is the long-term trend for Cytek Biosciences, Inc.'s operating cash flow?
- Over 2 years (2021 to 2025), Cytek Biosciences, Inc.'s operating cash flow has grown at a 1.8% compound annual growth rate (CAGR), from $4.63M to -$4.79M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Cytek Biosciences, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude